首页|期刊导航|Bone Research|RANKL inhibition reduces lesional cellularity and Gαs variant expression and enables osteogenic maturation in fibrous dysplasia
RANKL inhibition reduces lesional cellularity and Gαs variant expression and enables osteogenic maturation in fibrous dysplasia
Luis F.de Castro Jarred M.Whitlock Zachary Michel Kristen Pan Jocelyn Taylor Vivian Szymczuk Brendan Boyce Daniel Martin Vardit Kram Rebeca Galisteo Kamran Melikov Leonid V.Chernomordik Michael T.Collins Alison M.Boyce
Bone Research2024,Vol.12Issue(1):P.165-179,15.
Bone Research2024,Vol.12Issue(1):P.165-179,15.DOI:10.1038/s41413-023-00311-7
RANKL inhibition reduces lesional cellularity and Gαs variant expression and enables osteogenic maturation in fibrous dysplasia
摘要
关键词
dysplasia/treatment/finding分类
医药卫生引用本文复制引用
Luis F.de Castro,Jarred M.Whitlock,Zachary Michel,Kristen Pan,Jocelyn Taylor,Vivian Szymczuk,Brendan Boyce,Daniel Martin,Vardit Kram,Rebeca Galisteo,Kamran Melikov,Leonid V.Chernomordik,Michael T.Collins,Alison M.Boyce..RANKL inhibition reduces lesional cellularity and Gαs variant expression and enables osteogenic maturation in fibrous dysplasia[J].Bone Research,2024,12(1):P.165-179,15.基金项目
This work was supported by the Intramural Research Program of the NIDCR,NICHD ()
Clinical Center,National Institutes of Health.The clinical trial NCT03571191 was conducted as an investigator-sponsored study supported by Amgen,Inc ()
This research was supported in part by the NIDCR Genomics and Computational Biology Core:ZIC DC000086 ()
Veterinary Resources Core:ZIC DE000740-05.Work in the MTC and LVC laboratories was supported by the Research on Women’s Health(ORWH)through the Bench to Bedside Program award#884515. (ORWH)